环磷酰胺治疗后发生的膀胱癌。病例报告。

Bladder carcinoma following cyclophosphamide therapy. A case report.

作者信息

Kiesswetter H, Baloch N, Flamm J

出版信息

Int Urol Nephrol. 1985;17(2):139-42. doi: 10.1007/BF02082484.

DOI:10.1007/BF02082484

Abstract

Cyclophosphamide was introduced in 1958 in an effort to minimize the side effects of nitrogen mustard. Cyclophosphamide (Cytoxan, Endoxan) is not an alkylating agent which has been used for the treatment of a variety of non-malignant as well as malignant diseases. It has also recently been the focus of considerable interest as an immunosuppressive agent, perhaps the most potent immunosuppressive drug that has been synthesized. Reports of urologic complications from this drug are haemorrhagic cystitis, vesical fibrosis and urothelial carcinoma.

摘要

环磷酰胺于1958年被引入，旨在尽量减少氮芥的副作用。环磷酰胺（癌得星、Endoxan）并非一种用于治疗多种非恶性及恶性疾病的烷化剂。最近，它作为一种免疫抑制剂也备受关注，或许是已合成的最有效的免疫抑制药物。关于这种药物引起的泌尿系统并发症的报告有出血性膀胱炎、膀胱纤维化和尿路上皮癌。

相似文献

1

Bladder carcinoma following cyclophosphamide therapy. A case report.

Int Urol Nephrol. 1985;17(2):139-42. doi: 10.1007/BF02082484.

2

Urothelial carcinoma after cyclophosphamide therapy.

J Urol. 1983 Jan;129(1):143-4. doi: 10.1016/s0022-5347(17)51964-3.

3

[Urothelial cancers from Endoxan].

J Urol (Paris). 1984;90(6):411-2.

4

[Urothelial carcinoma after treatment with cyclophosphamide. Review of the literature and presentation of our caseload].

Actas Urol Esp. 1993 Feb;17(2):139-42.

5

Cyclophosphamide and carcinoma of bladder.

Urology. 1978 Apr;11(4):352-6. doi: 10.1016/0090-4295(78)90230-3.

6

Transitional cell carcinoma of the bladder associated with cyclophosphamide.

J Urol. 1974 Nov;112(5):603-4. doi: 10.1016/s0022-5347(17)59806-7.

7

Cyclophosphamide and the bladder.

Br Med J. 1971 Jul 17;3(5767):182. doi: 10.1136/bmj.3.5767.182-a.

8

Bladder cancer following administration of cyclophosphamide.

Urology. 1980 Aug;16(2):145-8. doi: 10.1016/0090-4295(80)90068-0.

9

Bladder cancer after cyclophosphamide therapy for lupus nephritis.

Nephron. 1992;60(3):378-9. doi: 10.1159/000186790.

10

[Urothelial carcinoma of the bladder following cyclophosphamide therapy].

Z Urol Nephrol. 1984 Jan;77(1):7-9.

本文引用的文献

1

Cyclophosphamide and urinary bladder toxicity.

Cancer Res. 1961 Dec;21:1577-89.

2

Uroepithelial carcinoma in association with cyclophosphamide ingestion.

J Urol. 1981 Oct;126(4):544-5. doi: 10.1016/s0022-5347(17)54619-4.

3

Bladder malignancy in patient receiving cyclophosphamide for benign disease.

Urology. 1981 Jul;18(1):80-1. doi: 10.1016/0090-4295(81)90503-3.

4

Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease.

Cancer. 1981 Aug 1;48(3):691-5. doi: 10.1002/1097-0142(19810801)48:3<691::aid-cncr2820480306>3.0.co;2-c.

5

Bladder tumour after treatment for lymphoma.

Med J Aust. 1981 Feb 21;1(4):190. doi: 10.5694/j.1326-5377.1981.tb135449.x.

6

Transitional cell carcinoma of the ureter associated with cyclophosphamide therapy for benign disease: a case report.

J Urol. 1982 Nov;128(5):1023-4. doi: 10.1016/s0022-5347(17)53327-3.

7

Urothelial carcinoma after cyclophosphamide therapy.

J Urol. 1983 Jan;129(1):143-4. doi: 10.1016/s0022-5347(17)51964-3.

8

[Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].

Arzneimittelforschung. 1982;32(5):486-7.

9

Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit.

Br Med J (Clin Res Ed). 1982 Apr 17;284(6323):1160-1. doi: 10.1136/bmj.284.6323.1160.

10

Bladder cancer following administration of cyclophosphamide.

Urology. 1980 Aug;16(2):145-8. doi: 10.1016/0090-4295(80)90068-0.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。